Gilead/Merck’s Lenacapavir/Islatravir Combination Could Help With HIV Stigma

Gilead presented 48-week data for the combination of weekly oral lenacapavir/islatravir, showing results consistent with 24-week data. A Phase III program will soon begin.

Gilead

The latest data from the Phase II study of the weekly oral combination of Gilead Sciences Inc.’s lenacapavir and Merck & Co., Inc.’s islatravir in patients living with HIV shows that efficacy is holding up compared with earlier data presented seven months ago, and now the combination is about to head into Phase III. But it will especially make a difference for patients who have difficulty in a psychological sense with having to take a pill to manage their disease every day.

Key Takeaways
  • Data at IDWeek from the Phase II study of the weekly oral combination of Gilead’s lenacapavir and Merck’s islatravir showed that 24-week safety and efficacy numbers presented in March have held up at 48 weeks.

Gilead presented 48-week data from the Phase II study in a late-breaking abstract at IDWeek on 19 October, an update...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Therapy Areas

Metabolic Disease-Focused Poxel Teeters On The Edge

 

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

UCB Takes A Bow as Bimzelx HS Launch Achieves Lift-Off

 
• By 

The Belgian company has raised its outlook for full-year sales following a strong launch for Bimzelx in hidradenitis suppurativa in the first half of 2025.

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By 

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By 

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

More from R&D

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.